Evidence map›Paper›PMID 35711068›Full record

ArticleAAPS PharmSciTech2022

A Hypoxia-Sensitive Drug Delivery System Constructed by Nitroimidazole and its Application in the Treatment of Hepatocellular Carcinoma.

Tingting Meng, Yinghong Li, Ying Tian, Mingxing Ma, Kequan Shi, Xuwei Shang, Hong Yuan, Fuqiang Hu

Abstract read
PubMed Publisher
In one paragraph

Article in AAPS PharmSciTech, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Responsive biomaterials for therapeutic strategies of hepatocellular carcinoma.Frontiers in bioengineering and biotechnology · 2025
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Tingting MengCollege of Pharmaceutical Science, Zhejiang University, Hangzhou, People's Republic of China.
Yinghong LiZhejiang Institute for Food and Drug Control, NMPA Key Laboratory for Testing and Warning of Pharmceutical Microbiology, Key Laboratory of Drug Contacting Materials Quality Control of Zhejiang Province, Hangzhou, People's Republic of China.
Ying TianDepartment of Pharmacy, Qingdao Fifth People's Hospital, Qingdao City, People's Republic of China.
Mingxing MaDepartment of Pharmacy, Qingdao Fifth People's Hospital, Qingdao City, People's Republic of China.
Kequan ShiCollege of Pharmaceutical Science, Zhejiang University, Hangzhou, People's Republic of China.
Xuwei ShangCollege of Pharmaceutical Science, Zhejiang University, Hangzhou, People's Republic of China.
Hong YuanCollege of Pharmaceutical Science, Zhejiang University, Hangzhou, People's Republic of China.
Fuqiang HuCollege of Pharmaceutical Science, Zhejiang University, Hangzhou, People's Republic of China. hufq@zju.edu.cn.
Zhejiang University · CNQingdao Eighth People's Hospital · CNZheJiang Institute For Food and Drug Control · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypoxia is an important pathological phenomenon, and it can induce many tumor microenvironment changes, such as accumulations of intracellular lactic acid, decrease of tumor microenvironment pH value, and regulate a series of physiological and pathological processes such as adhesion, metastasis, and immune escape. Hypoxic tumor cells act as a key target for treating tumor. In this research, we designed and prepared PEG-nitroimidazole grafts, PEG-NI, and FA-PEG-NI. We first explored their physical and chemical properties to serve as a drug carrier. Then, the hypoxia-sensitive properties such as particle size changes and drug release were investigated. Finally, the tumor targeting ability was studied in vitro and in vivo, and anti-tumor capacity was determined. Both grafts showed excellent property as a nanodrug carrier and showed favorable drug encapsulation ability of sorafenib with the help of the hydrophobic chain of 6-(BOC-amino) hexyl bromide. The micelles responded to the hypoxic tumor environment with chemical and spatial structure changes leading to sensitive and fast drug release. With the modification of folic acid, FA-PEG-NI gained tumor targeting ability in vivo. FA-PEG-NI graft proved a potential targeting drug delivery system in the treatment of hypoxic hepatocellular carcinoma.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsNitroimidazolesCell Line, TumorDrug CarriersDrug Delivery SystemsFolic AcidHumansHypoxiaMicellesPolyethylene GlycolsTumor MicroenvironmentAntineoplastic AgentsDrug CarriersFolic AcidMicellesNitroimidazolesPolyethylene Glycolsfolic acidhepatocellular carcinomahypoxia sensitivePEG-nitroimidazole grafts

Identifiers

PMID35711068
OpenAlexW4283012890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.